Exousia Pro, Inc. (OTCMKTS: MAJI), a clinical-stage biotech company, is redefining precision medicine through its innovative exosome-based drug delivery platform. By leveraging exosomes - nanoscale (30-100 nm) vesicles naturally produced by cells - Exousia is developing targeted therapies that surpass the limitations of monoclonal antibodies (mAbs). With applications in oncology, regenerative medicine, and dermatology, Exousia is positioned to capture significant value in the rapidly growing exosome market. The company has a number of upcoming catalysts that could drive a parabolic trajectory.
Exosomes: The Next-Generation Delivery Vehicle
Exosomes, once dismissed as cellular debris, are now recognized as vital mediators of intercellular communication and nutrient transport. Exousia's patented platform enables the infusion of drugs, proteins, or nuclear DNA into exosomes engineered to target specific tissues or diseased cells. Compared to mAbs, exosomes offer compelling advantages:
- Immune Evasion: Invisible to the immune system, reducing adverse reactions.
- Blood-Brain Barrier Penetration: Unlike mAbs (only 0.2% cross), exosomes excel in neurological applications.
- Versatile Delivery: Administered intranasally, subcutaneously, or topically, avoiding invasive injections.
- Precision Targeting: Customizable outer shells ensure pinpoint delivery to specific cells.
Manufacturing Breakthrough
Exosome therapies have been hard to scale because making them usually involves many complicated steps. Exousia has developed a new way to solve this problem. They use stem cells to create exosomes in just one step. These exosomes carry specific surface markers and medicine inside, which makes them highly pure and easier to produce in large amounts. They also meet safety standards and cost less to make.
Lead Program: Glioblastoma (GBM)
Exousia's lead treatment focuses on glioblastoma, a very aggressive type of brain cancer. It uses a mix of gene therapy and chemotherapy to attack cancer stem cells - these cells usually resist normal treatments. Lab tests showed that even a small amount of the therapy caused cancer cells to die. In mouse studies, normal doses worked well and showed clear benefits. The treatment also targets a marker that may help doctors spot glioblastoma more easily.
Clinical Results: Temozolomide + miRNA Combination Therapy
Key Results
Demonstrated a combination therapy of exosomal delivery of a silencing gene reduced the drug resistance mechanisms of GBM and helped kill 77-94% of cancer stem cells.
- Low non-toxic levels of Temozolomide (TMZ) in combination with exosome roughly triple the effect of a very high dose
- Conventional therapy: Temozolomide (TMZ) can only kill 25% of cancer stem cells, even at a very high (mM) dose
- Nearly 100% efficacy at optimal dosing
Exousia plans to apply for special approval called Orphan Drug Designation by late 2025. They also hope to begin early compassionate use trials to collect real-world evidence and build partnerships with major drug companies. The team is working to expand this approach to other cancers like pancreatic, breast, and colorectal, using advanced tools like AI.
Dermatological and Nutraceutical Applications
Exousia is developing exosomes made from mushrooms that are rich in nutrients. These plant-based exosomes can help improve skin health and promote hair growth. The company is also exploring ways to use these in other health products, especially in regenerative medicine. This opens doors to exciting new markets like skincare and beauty supplements.
Market Opportunity
The exosome market is growing fast - from about $304 million in 2024 to over $1.1 billion by 2032. Exousia is in a great position to lead this space, thanks to its technology that can be used in cancer, brain disorders, inflammation, and tissue repair. Other markets, like monoclonal antibodies ($235.8 billion in 2024) and antibody-drug combinations ($13.5 billion in 2025), are also large but have certain limits. Exousia's approach helps overcome these challenges, giving it an edge over traditional treatments.
Management Team
In biotech companies, the management team is one of the most important things investors look at. Exousia's leadership brings together extensive experience in biotech operations, clinical development, and strategic partnerships.
Mike Sheikh
Over 5 years of leadership experience in biotech. Known for working effectively with limited resources and has helped pitch deals and partnerships.
Matt Dwyer
Brings strong operational skills - ensures the company's paperwork is up to date and is focused on getting the company listed on a bigger stock exchange.
Dr. Marvin Hausman
Well-known expert with deep experience in clinical trials and drug licensing, helping the company get orphan drug approval.
Financial Position
Exousia has a market capitalization of $5 million, with 40 million outstanding shares (8.5 million at DTC) and 84 shareholders of record. A FINRA name change is pending, and the company is ensuring its books are done properly in preparation for an uplisting.
Investment Summary
Exousia Pro, Inc. (MAJI) is a biotech company with exciting potential in the fast-growing field of exosome therapy. Its special one-step method for making exosomes solves key problems that have made scaling difficult. This gives Exousia a strong position in a market expected to grow nearly 30% every year until 2032.
One of its top projects focuses on glioblastoma, a tough form of brain cancer. With plans to get Orphan Drug status soon, the company is using early lab data and a targeted approach that looks very promising. Exousia also uses AI and special FDA pathways to attract major drug companies and unlock big deals.
Beyond cancer, the company is working on treatments for skin health and nutrition, helping to grow its revenue opportunities. Its leadership team is small but experienced, helping the company grow efficiently. With a market value of just $5 million and strong insider ownership, Exousia could be a hidden gem for investors looking for big returns in biotech.